MCIM
SRPT icon

Meadow Creek Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Meadow Creek Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$27K Buy
364
+112
+44% +$13.2K ﹤0.01% 1304
2019
Q2 		$38K Hold
252
– – ﹤0.01% 1299
2019
Q1 		$30K Buy
252
+28
+13% +$3.6K ﹤0.01% 1294
2018
Q4 		$24K Buy
+224
New +$28K ﹤0.01% 1252

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Meadow Creek Investment Management's SRPT Position: Q3 2019 in Review

Meadow Creek Investment Management increased its Sarepta Therapeutics (SRPT) stake by 44% in Q3 2019, buying an estimated $13.2K and bringing the position to 364 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Meadow Creek Investment Management first reported a position in SRPT in Q4 2018 and has held it in 4 quarters since. The position peaked at $38K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Meadow Creek Investment Management held 364 shares of Sarepta Therapeutics worth $27K as of Q3 2019.
  • Meadow Creek Investment Management bought 112 Sarepta Therapeutics shares in Q3 2019, an estimated $13.2K.
  • Sarepta Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1304 holding.
  • Meadow Creek Investment Management first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Meadow Creek Investment Management's Sarepta Therapeutics position peaked at $38K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.